Cited by 106Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesHead and Neck Cancer Studies

Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: A randomized controlled trial with at least 5-year follow-up

Roozeboom, Marieke H., Aardoom, Martine A., Nelemans, Patty J., Thissen, Monique R.T.M., Kelleners-Smeets, Nicole W.J., Kuijpers, Danielle I.M., Mosterd, Klara·2013·Journal of the American Academy of Dermatology

Abstract

Background Although effective in superficial basal cell carcinoma (BCC), the treatment effect of photodynamic therapy (PDT) in nodular BCC (nBCC) is still questionable. The relation between tumor thickness and PDT failure is unclear.Objective We sought to compare long-term effectiveness of fractionated 20% 5-aminolevulinic acid (ALA)-PDT with prior partial debulking versus surgical excision in nBCC. The effect of tumor thickness on ALA-PDT failure was analyzed.Methods 173 primary, histologically proven nBCCs in 151 patients were randomized to fractionated ALA-PDT (n = 85) or surgical excision (n = 88). Two PDT illuminations were performed with a 1-hour interval. Follow-up was at least 5 years posttreatment. Clinical recurrences were confirmed histologically.Results A total of 171 nBCCs were treated and had a median follow-up of 67 months (range 0-106). At 60 months, 23 tumors had recurred in the ALA-PDT group and 2 tumors in the surgical excision group. Cumulative recurrence probabilities 5 years posttreatment were 30.7% (95% confidence interval [CI] 21.5%-42.6%) for ALA-PDT and 2.3% (95% CI 0.6%-8.8%) for surgical excision (P < .0001). Two tumors in the ALA-PDT group recurred at 72 and 91 months posttreatment. Cumulative probability of recurrence-free survival post-PDT was 65.0% (95% CI 51%-76%) for nBCC measuring greater than 0.7 mm in thickness and 94.4% (95% CI 67%-99%, P = .018) for tumors less than or equal to 0.7 mm.Limitations Tumor thickness on punch biopsy specimen might differ from the total lesion thickness.Conclusions In nBCC, 5-year cumulative probability of recurrence after surgical excision is lower than after fractionated ALA-PDT with prior debulking. Although surgical excision remains the gold standard of treatment, PDT might be an alternative for inoperable patients with thin (≤0.7 mm) nBCC.

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2013.02.014

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MAL PDT is a more effective treatment option than ALA PDT for nodular BCC.

    “Methylaminolevulinate (MAL) PDT is a more effective treatment option than 5-aminolevulinic acid (ALA) PDT for nodular BCC.”

    From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [52]

  • ALA/PDT was found to have a 30.7% recurrence rate for treatment of nodular BCC in one study.

    “Whereas ALA/PDT was found to have a 30.7% recurrence rate for treatment of nodular BCC in one study [52]”

    From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [52]

The citation lists haven’t been fetched yet

References 43 · Cited by 106

Authors
Roozeboom, M. H., Aardoom, M. A., Nelemans, P. J., Thissen, M. R. T. M., Kelleners-Smeets, N. W. J., Kuijpers, D. I. M., & Mosterd, K.
Affiliations
Maastricht University Medical Centre (NL)
Corresponding author
Roozeboom, Marieke H.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2013-08
Volume
69
Issue
2
Pages
280-287
ISSN
0190-9622 (ISSN-L)
OpenAlex
W2020590528
Cited by
106
References
43
Citations by year
2026: 5 · 2025: 9 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 15 · 2014: 8
FWCI
8.03
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Academy of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
nodular basal cell carcinoma, 5-aminolevulinic acid photodynamic therapy, surgical excision, tumor thickness, recurrence, recurrence-free survival, long-term follow-up, treatment comparison, recurrence risk factors, cost-effectiveness
MeSH terms
Adult, Aged, Aged, 80 and over, Aminolevulinic Acid, Carcinoma, Basal Cell, Basal Cell Carcinoma, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Photochemotherapy, Skin Neoplasms, Time Factors, Confidence Intervals, Survival Analysis, Treatment Outcome, Risk Assessment, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult, Dermatologic Surgical Procedures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review